KRRO
Korro Bio, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Korro Bio, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Bull2
Bear1
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| Lynx1 | $20.3M | 10.57% | 0.00% |
| NEA | $17.1M | 8.92% | 0.00% |
| VR Adviser | $13.3M | 6.94% | 0.00% |
| Atlas Venture Life Science | $12.7M | 6.61% | −15.32% |
| Balyasny | $12.5M | 6.54% | −8.49% |
| Manager | Value | % base | |
|---|---|---|---|
| Lynx1 | $20.3M | 10.57% | 0.00% |
| NEA | $17.1M | 8.92% | 0.00% |
| VR Adviser | $13.3M | 6.94% | 0.00% |
| Atlas Venture Life Science | $12.7M | 6.61% | −15.32% |
| Balyasny | $12.5M | 6.54% | −8.49% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Korro Bio, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Korro Bio, Inc.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Expected move
Inputs8Q avg ±16.9%·×1.63·rich
straddle ±28.1%
spot 15.86exp Nov 20ATM strike 15ATM straddle 5.25IV 198%
Korro Bio, Inc.
16.27
+0.41 · +2.57%